AI assistant
GlaxoSmithKline PLC Director's Dealing 2025
5262_dirs_2025-06-12_0f823b10-fc8b-45eb-afde-4e4876293195.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
GSK Plc - Director/PDMR Shareholding
PR Newswire
LONDON, United Kingdom, June 12
GSK plc (the ‘Company’)
Transaction notification
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 9 (partnership shares) | ||||
| £14.9465 | 9 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 18 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Julie Brown | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price |
16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Sally Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Philip Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
| a) | Name | Victoria Whyte | |||
| b) | Position/status | Company Secretary | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £14.9465 | 8 (partnership shares) | ||||
| £14.9465 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £14.9465 |
||||
| e) | Date of the transaction | 2025-06-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
